IBN Stock Analysis: ICICI Bank | NYSE
Banks - Regional | NYSE, USA | Market Cap: 105.976m USD | 12M Return: -12% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 207M
EPS Trend: 92.1%
Qual. Beats: 0
Rev. Trend: 95.9%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
ICICI Bank Limited is an Indian financial services group that provides a wide range of banking and related services to retail and corporate customers in India and abroad. Its operations are organized across multiple segments, including Retail Banking, Wholesale Banking, Treasury, Life Insurance, General Insurance, and Other Banking activities. Founded in 1955 and headquartered in Mumbai, the bank is listed in the U.S. through ADRs trading on the NYSE under the ticker IBN.
The companys offerings span the full retail and commercial banking stack: deposit accounts (savings, salary, current, fixed, and foreign currency accounts), lending products (home, auto, personal, education, gold, commercial, working capital, and trade finance), credit and debit cards, digital wallets, investment and broking services, and wealth management. Beyond traditional banking, ICICI also provides life and general insurance, asset management, custodial services, trusteeship, and venture capital fund management, making it one of Indias large diversified private-sector banks.
Indian diversified banks like ICICI typically derive revenue from a mix of net interest income (the gap between loan and deposit rates) and fee-based income from cards, distribution, transaction banking, and insurance, which helps diversify earnings across the credit cycle. The Indian banking sector remains structurally supported by a large under-banked retail population, growing credit penetration, and the countrys broader role as an emerging-market financial center.
- RBI rate cuts compress net interest margins on lending portfolio
- Retail loan growth accelerates in mortgages and personal credit
- Insurance subsidiaries deliver rising fee income and dividends
| Net Income: 543b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.75 > 1.0 |
| NWC/Revenue: -500.3% < 20% (prev -484.6%; Δ -15.67% < -1%) |
| CFO/TA 0.02 > 3% & CFO 673b > Net Income 543b |
| Net Debt (-447b) to EBITDA (805b): -0.56 < 3 |
| Current Ratio: 0.14 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.62b) vs 12m ago 1.12% < -2% |
| Gross Margin: 69.67% > 18% (prev 68.11%; Δ 1.56% > 0.5%) |
| Asset Turnover: 11.26% > 50% (prev 11.15%; Δ 0.11% > 0%) |
| Interest Coverage Ratio: 0.87 > 6 (EBIT TTM 774b / Interest Expense TTM 892b) |
| A: -0.54 (Total Current Assets 2650b - Total Current Liabilities 18300b) / Total Assets 29145b |
| B: 0.01 (Retained Earnings 319b / Total Assets 29145b) |
| C: 0.03 (EBIT TTM 774b / Avg Total Assets 27784b) |
| D: 0.14 (Book Value of Equity 3631b / Total Liabilities 25349b) |
| Altman-Z'' = -3.15 = D |
As of July 05, 2026, the stock is trading at USD 29.49 with a total of 5,110,000 shares traded. Over the past week, the price has changed by +1.20%, over one month by +15.65%, over three months by +13.16% and over the past year by -11.96%.
Current recommended Stop Loss: 28.40 (which is 3.7% or 2.1 ATR below the current price).
ICICI Bank has received a consensus analysts rating of 4.75. Therefore, it is recommended to buy IBN.
- StrongBuy: 3
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 35.4 | 20% |
Market Cap INR = 10110b (106b USD * 95.4 USD.INR)
P/E Trailing = 18.7025
P/E Forward = 17.7305
P/S = 0.0487
P/B = 2.7567
P/EG = 0.5248
Revenue TTM = 3128b INR
EBIT TTM = 774b INR
EBITDA TTM = 805b INR
Long Term Debt = 2203b INR (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 2203b INR (from shortLongTermDebtTotal, last quarter)
Net Debt = -447b INR (calculated: Debt 2203b - CCE 2650b)
Enterprise Value = 9663b INR (10110b + Debt 2203b - CCE 2650b)
Interest Coverage Ratio = 0.87 (Ebit TTM 774b / Interest Expense TTM 892b)
EV/FCF = 15.19x (Enterprise Value 9663b / FCF TTM 636b)
FCF Yield = 6.58% (FCF TTM 636b / Enterprise Value 9663b)
FCF Margin = 20.33% (FCF TTM 636b / Revenue TTM 3128b)
Net Margin = 17.36% (Net Income TTM 543b / Revenue TTM 3128b)
Gross Margin = 69.67% ((Revenue TTM 3128b - Cost of Revenue TTM 949b) / Revenue TTM)
Gross Margin QoQ = 73.64% (prev 68.09%)
Tobins Q-Ratio = 0.33 (Enterprise Value 9663b / Total Assets 29145b)
Interest Expense / Debt = 40.50% (Interest Expense 892b / Debt 2203b)
Taxrate = 25.07% (194b / 775b)
NOPAT = 580b (EBIT 774b * (1 - 25.07%))
Current Ratio = 0.14 (Total Current Assets 2650b / Total Current Liabilities 18300b)
Debt / Equity = 0.61 (Debt 2203b / totalStockholderEquity, last quarter 3631b)
Debt / EBITDA = -0.56 (Net Debt -447b / EBITDA 805b)
Debt / FCF = -0.70 (Net Debt -447b / FCF TTM 636b)
Total Stockholder Equity = 3442b (last 4 quarters mean from totalStockholderEquity)
RoA = 1.95% (Net Income 543b / Total Assets 29145b)
RoE = 15.78% (Net Income TTM 543b / Total Stockholder Equity 3442b)
RoCE = 13.71% (EBIT 774b / Capital Employed (Equity 3442b + L.T.Debt 2203b))
RoIC = 5.43% (NOPAT 580b / Invested Capital 10688b)
WACC = 11.15% (E(10110b)/V(12313b) * Re(6.97%) + D(2203b)/V(12313b) * Rd(40.50%) * (1-Tc(0.25)))
Discount Rate = 6.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 80.90 | Cagr: 0.64%
[DCF] Terminal Value 63.41% ; FCFF base≈691b ; Y1≈606b ; Y5≈490b
[DCF] Fair Price = 1.63k (EV 5393b - Net Debt -447b = Equity 5840b / Shares 3.59b; r=11.15% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 92.12 | EPS CAGR: 9.67% | SUE: 0.77 | # QB: 0
Revenue Correlation: 95.95 | Revenue CAGR: 22.14% | SUE: 2.61 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.41 | Chg30d=-4.68% | Revisions=-25% | Analysts=1
EPS next Quarter (2026-09-30): EPS=0.39 | Chg30d=-3.19% | Revisions=-25% | Analysts=1
EPS current Year (2027-03-31): EPS=1.69 | Chg30d=-5.19% | Revisions=-40% | GrowthEPS=+13.0% | GrowthRev=+13.8%
EPS next Year (2028-03-31): EPS=1.91 | Chg30d=-4.79% | Revisions=-25% | GrowthEPS=+13.1% | GrowthRev=+14.5%
[Analyst] Revisions Ratio: -62% (up=0, down=5)